Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 15/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820199 | 1.00 | P2RY6 (0.63) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL148675 | 0.92 | P2RY6 (0.73) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL148676 | 0.92 | P2RY6 (0.73) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL17971963 | 0.91 | P2RY2 (0.56) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL21418568 | 0.91 | P2RY2 (0.56) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL17971955 | 0.91 | P2RY2 (0.57) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL17976672 | 0.91 | P2RY2 (0.57) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL21418570 | 0.91 | P2RY2 (0.57) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL17976690 | 0.91 | P2RY2 (0.56) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL9702618 | 0.90 | P2RY6 (0.74) | P2RY6P2RY2P2RY14NT5EP2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063651-A1 | Remedies for hepatitis c | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346724-A1 | REMEDIES FOR HEPATITIS C | Mitsubishi Pharma Corporation (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20040063651-A1 | Remedies for hepatitis c | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346724-A1 | REMEDIES FOR HEPATITIS C | Mitsubishi Pharma Corporation (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063651-A1 | Remedies for hepatitis c | UPP1, UMPS, UNG | P2RY6 2156/4885P2RY2 3348/4885P2RY14 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.